Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
LancetSep 9, 2026 (epub)
Yelena Y Janjigian, Salah-Eddin Al-Batran, Zev A Wainberg et al.
✦ AI-curated · Sources linked
In 30 seconds
The MATTERHORN trial, a global, randomised, double-blind, placebo-controlled phase 3 study, evaluated the effect of perioperative durvalumab plus FLOT in 948 adults with resectable gastric and gastro-oesophageal junction adenocarcinoma. The study found that overall survival significantly improved in the durvalumab group compared to placebo, with a hazard ratio of 0.78 (95% CI 0.63-0.96; p=0.021).
Key findings
- Overall survival improved with durvalumab versus placebo, hazard ratio 0.78 (95% CI 0.63-0.96; p=0.021).
- The trial enrolled 1258 participants, with 948 randomly assigned to treatment groups.
- Adverse events possibly related to treatment occurred in 1% of the durvalumab group.
- The study established durvalumab plus FLOT as a new standard treatment option.
Why it matters
This study provides evidence for a new treatment regimen that enhances overall survival in patients with resectable gastric and gastro-oesophageal junction adenocarcinoma, potentially influencing clinical practice and treatment guidelines.